RADX

Across TCGA pan-cancer cohorts, RADX mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RADX data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RADX mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RADX expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where RADX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	1.000	0.859	.027	8	view →
LSCC	DFS	Tertile	All	0.290	1.000	.010	6	view →
GBM	OS	Tertile	All	0.949	0.768	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RADX–CCRCC (OS)

Open the CCRCC breakdown →